Journals / art / 2018 / Cilt: 33 - Sayı: 3

Paricalcitol Inhibits Wnt/β-Catenin Signaling Pathway and Ameliorates Dermal Fibrosis in Bleomycin Induced Scleroderma Model

Journal
art
Pages
288–294
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In this model, increased axin-1 and Wnt-2 mRNA expressions suggest that Wnt/β-catenin pathway is active in dermal fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to determine the prophylactic and therapeutic efficacy of inhibition of Wnt/β-catenin signaling pathway with paricalcitol in an experimental scleroderma model created with bleomycin (BLM).
📊
Key Findings & Data:Materials and methods: Sixty female BALB/c mice (8-week old and weighing 25 g to 30 g) were divided into six groups as prophylactic-early [control I (group 1)], sham I (group 2), paricalcitol I (group 3), therapeutic-late [control II (group 4)], sham II (group 5), and paricalcitol II (group 6) groups.
💡
Conclusion & Impact:Conclusion: In this model, increased axin-1 and Wnt-2 mRNA expressions suggest that Wnt/β-catenin pathway is active in dermal fibrosis.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to determine the prophylactic and therapeutic efficacy of inhibition of Wnt/β-catenin signaling pathway with paricalcitol in an experimental scleroderma model created with bleomycin (BLM). Materials and methods: Sixty female BALB/c mice (8-week old and weighing 25 g to 30 g) were divided into six groups as prophylactic-early [control I (group 1)], sham I (group 2), paricalcitol I (group 3), therapeutic-late [control II (group 4)], sham II (group 5), and paricalcitol II (group 6) groups. Subcutaneous BLM (100 μg/day) injections were used to induce dermal fibrosis and paricalcitol (0.3 µg/kg/day) was applied subcutaneously to BLM-injected mice during the first three weeks for preventive interventions and in the second three weeks for therapeutic interventions. Tissue samples were harvested for subsequent pathological and real-time polymerase chain reaction (RT-PCR) analysis. Tissue transforming growth factorbeta 1 (TGF-β1), axin-1, and Wnt-2 messenger ribonucleic acid (mRNA) expressions were determined by RT-PCR. Results: Repeated BLM applications increased the dermal inflammatory cell infiltration and dermal thickness, and led to dermal fibrosis, in both early and late stages. Similarly, TGF-β1, axin-1, and Wnt-2 expressions were significantly increased in the sham groups compared to the own control group (p<0.05 for all). Contrarily, prophylactic and therapeutic paricalcitol applications decreased the TGF-β1, axin-1, and Wnt-2 mRNA expressions compared to the own sham group (p<0.05 for all). In addition, the regressions in dermal necro-inflammation and dermal fibrosis on pathological views were also observed in the paricalcitol applied groups. Conclusion: In this model, increased axin-1 and Wnt-2 mRNA expressions suggest that Wnt/β-catenin pathway is active in dermal fibrosis.

🔖

Cite This Article

GÖZEL, N., DURAN, F., YILDIRIM, A., YOLBAŞ, S., ÖNALAN, E., ÖZERCAN, İ. H., KOCA, S. S. (2018). Paricalcitol Inhibits Wnt/β-Catenin Signaling Pathway and Ameliorates Dermal Fibrosis in Bleomycin Induced Scleroderma Model. art, Cilt: 33 - Sayı: 3, 288–294. https://ajindex.com/articles/158132

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Nolan KA, Brennan EP, Scholz CC, Cullen C, Ryan A, Taylor CT, et al. Paricalcitol protects against TGF-b1-induced fibrotic responses in hypoxia and stabilises HIF-a in renal epithelia. Exp Cell Res 2015;330:371-81.
  2. Piao SG, Song JC, Lim SW, Chung BH, Choi BS, Yang CW. Protective effect of paricalcitol on cyclosporine-induced renal injury in rats. Transplant Proc 2012;44:642-5.
  3. Park JW, Cho JW, Joo SY, Kim CS, Choi JS, Bae EH, et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012;683:301-9. Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999;21:432-41.
  4. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008;128:871-81. Yamamoto T. Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma? Clin Immunol 2002;102:209-16.
  5. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-93.
  6. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/b-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90-103.
  7. Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006;21:799-809. Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of betacatenin signaling. J Cell Biol 2001;154:369-87.
  8. Lemaire R, Farina G, Bayle J, Dimarzio M, Pendergrass SA, Milano A, et al. Antagonistic effect of the matricellular signaling protein CCN3 on TGF-beta- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome. J Invest Dermatol 2010;130:1514-23.
  9. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt/b-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012;64:2734-45.
  10. Farina G, Lafyatis D, Lemaire R, Lafyatis R. A fourgene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2